HAYWARD, Calif., April 10, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated announced data will be presented on the Company's clinical and preclinical pipeline, including its Hsp90 inhibitor, epothilone and nuclear export inhibitor programs, at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, April 14-18, 2007.
Poster presentations on Kosan's programs are as follows. The location for all poster presentations is the Los Angeles Convention Center Exhibit Hall.
Date Abstract # Title Session Poster Poster # Section 4/15 1:00- 1544 Tanespimycin: Experimental 32 4 5:00 No effects on and Molecular QTC interval Therapeutics 13 using two formulations 4/15 1:00- 1568 Preclinical Experimental 32 28 5:00 safety profile and Molecular of tanespimycin Therapeutics 13 (KOS-5: 953) -- a heat shock protein 90 (Hsp90) inhibitor 4/15 1:00- 1438 KOS-1803: A new, Experimental 27 19 5:00 rationally and Molecular designed Therapeutics 8 epothilone analog with an improved pharmacological profile and efficacy in xenograft mouse models 4/18 8:00- 5597 Anti-tumor Experimental 29 2 12:00 activity of and Molecu lar novel nuclear Therapeutics 47 export inhibitors (NEIs) in multiple xenograft models 4/18 8:00- 5609 Nuclear Export Experimental 29 14 12:00 Inhibitors and Molecular (NEIs) as novel Therapeutics 47 cancer therapeutics
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.
For additional information on Kosan Biosciences, please visit the company's website at www.kosan .com.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding anticipated presentations of data relating to Kosan's product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, the risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2006 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.
NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.
CONTACT: Jane Green, VP, Corporate Communications of Kosan BiosciencesIncorporated, +1-510-731-5335, or mobile, +1-415-652-4819, or email@example.com
Web site: http://www.kosan.com/
Ticker Symbol: (NASDAQ-NMS:KOSN)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company